Neurosteroids and Postpartum Depression: The Mechanism, Efficacy, and Approval of Brexanolone and Zurzuvae
Robert B. Kargbo
Abstract
Postpartum depression (PPD) affects 10-15% of new mothers globally. Marking a pivotal shift in treatment, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone) as the first oral medication for PPD in adults. This major depressive episode can emerge after childbirth or in pregnancy's later stages. Previously, PPD treatments were restricted to IV injections administered in select healthcare facilities. Childbirth instigates hormonal, physiological, and emotional shifts, with a stark drop in mood-regulating hormones like estrogen and progesterone possibly triggering depression. The role of serotonin in PPD is undeniable. Psychosocial stressors, such as neonatal care burdens and societal pressures, further amplify the risk. This Patent Highlight underscores the introduction of zuranolone as a beacon of hope for an effective and accessible treatment, which may benefit many postnatal women worldwide.